Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Dec 21, 2009; 15(47): 5946-5952
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946
Table 2 Virological response rates by study group n (%)
| PR group (n = 15) | PK group (n = 16) | PRK group (n = 14) | P-value | |
| Virological response rate | ||||
| Week 1 | 0 | 0 | 1 (7.1) | NS |
| Week 2 | 1 (6.7) | 1 (6.3) | 2 (14.3) | NS |
| Week 4 | 5 (33.3) | 2 (12.5) | 3 (21.4) | NS |
| Week 12 | 10 (66.7) | 7 (43.8) | 7 (50) | NS |
| Week 24 | 11 (73.3) | 11 (68.8) | 10 (71.4) | NS |
| ETR | 11 (73.3) | 11 (68.8) | 10 (71.4) | NS |
| Relapse rate | 4/11 (36.4) | 6/11 (54.5) | 2/10 (20) | NS |
| SVR | 7 (46.7) | 5 (31.3) | 8 (57.1) | NS |
- Citation: Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. World J Gastroenterol 2009; 15(47): 5946-5952
- URL: https://www.wjgnet.com/1007-9327/full/v15/i47/5946.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5946